ErVimmune develops cancer vaccines and T cell therapies targeting cold tumors using AI-driven antigen discovery.
ErVimmune has raised $19.9M in total funding. The most recent round was Series A. The last funding was announced in January 2026.
ErVimmune's investors include Seventure Partners, SPRIM Global Investments.
ErVimmune is headquartered in Lyon, France.
ErVimmune develops cancer vaccines and T cell therapies targeting cold tumors using AI-driven antigen discovery.
ErVimmune is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ErVimmune — Funding & Investors." VCBacked, January 21, 2026, https://www.vcbacked.co/company/ervimmune. Accessed July 22, 2026.
VCBacked. (2026). ErVimmune — Funding & Investors. Retrieved July 22, 2026, from https://www.vcbacked.co/company/ervimmune
{{cite web |title=ErVimmune — Funding & Investors |url=https://www.vcbacked.co/company/ervimmune |website=VCBacked |access-date=July 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated